Lee Li-Ang, Cheng Ann-Joy, Fang Tuan-Jen, Huang Chung-Guei, Liao Chun-Ta, Chang Joseph Tung-Chieh, Li Hsueh-Yu
Department of Otolaryngology, Chang Gung Memorial Hospital, Chang Gung University, 5 Fu-Shin Street, Kweishan, Taoyuan, Taiwan.
Laryngoscope. 2008 Jan;118(1):50-5. doi: 10.1097/MLG.0b013e318155a288.
Papillomas of the larynx include solitary laryngeal papilloma and recurrent respiratory papillomatosis. This study investigated the incidence of malignant transformation and assessed possible risk factors for laryngeal papillomas.
A prospective, longitudinal study.
Twenty-six consecutive laryngeal papilloma patients were prospectively studied for 5 or more years, and each patient was periodically examined at 3 to 6 month intervals. A detailed epidemiologic questionnaire was administered at the initial visit. After enrollment, tissue obtained during each laryngeal surgery was examined by polymerase chain reaction assay for human papilloma virus (HPV) and typing.
During 237 person-years of follow-up, six new, pathologically confirmed cases of laryngeal carcinoma were ascertained (incidence 2.5/100 person-years), and all were associated with HPV-6 or HPV-11. Malignant transformation revealed no correlation with the following: age less than 3 years at diagnosis, sex, history of tobacco use, history of alcohol consumption, family history of laryngeal cancer, or type of laryngeal papilloma. Laryngeal papilloma without demonstrable HPV DNA was the only significant risk factor for malignant transformation (P < .05). The cumulative risk of malignant transformation in subjects without demonstrable HPV DNA was significantly higher than that in HPV-positive patients (relative risk, 8.0; 95% confidence interval, 1.1-60.3; P = .05).
A relatively high incidence of malignant transformation of laryngeal papilloma was noted in Taiwanese patients. Patients without demonstrable HPV DNA require more frequent follow-up and may benefit from anti-HPV vaccinations.
喉乳头状瘤包括孤立性喉乳头状瘤和复发性呼吸道乳头状瘤病。本研究调查了恶性转化的发生率,并评估了喉乳头状瘤可能的危险因素。
一项前瞻性纵向研究。
对连续26例喉乳头状瘤患者进行了5年或更长时间的前瞻性研究,每位患者每隔3至6个月定期接受检查。在初次就诊时发放详细的流行病学调查问卷。入组后,对每次喉手术获取的组织进行聚合酶链反应检测,以检测人乳头瘤病毒(HPV)并进行分型。
在237人年的随访期间,确定了6例新的经病理证实的喉癌病例(发病率为2.5/100人年),所有病例均与HPV-6或HPV-11相关。恶性转化与以下因素无关:诊断时年龄小于3岁、性别、吸烟史、饮酒史、喉癌家族史或喉乳头状瘤类型。未检测到HPV DNA的喉乳头状瘤是恶性转化的唯一显著危险因素(P < 0.05)。未检测到HPV DNA的受试者恶性转化的累积风险显著高于HPV阳性患者(相对风险,8.0;95%置信区间,1.1 - 60.3;P = 0.05)。
台湾患者中喉乳头状瘤恶性转化的发生率相对较高。未检测到HPV DNA的患者需要更频繁的随访,并且可能从抗HPV疫苗接种中获益。